SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Lupus
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Tebbe, B.
Right arrow Articles by Orfanos, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tebbe, B.
Right arrow Articles by Orfanos, C.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Epidemiology and socioeconomic impact of skin disease in lupus erythematosus

B. Tebbe

Department of Dermatology, University Medical Benjamin Franklin, The Free University of Berlin, Berlin, Germany

CE Orfanos

Department of Dermatology, University Medical Benjamin Franklin, The Free University of Berlin, Berlin, Germany

The prevalence rates of systemic lupus erythematosus (SLE) may vary within 17-48/100 000 population worldwide. Although population-based epidemiological studies are still missing, the cutaneous variants of lupus erythematosus (LE) are 2-3 times more frequent than SLE itself. The most common age of onset is 20-40 y. Overall, cutaneous LE is regarded as a variant with less severe course and better prognosis. However, CDLE and SCLE last for many years and may lead, like SLE, to severe disability for work and limited life quality; also, a small proportion of patients with cutaneous LE develops SLE during the course of their disease. This implies considerable amount of medical management and costs for the community. Early recognition of cutaneous LE patients at risk to develop SLE and preventive measures against disease triggering factors are important tasks for physicians attending with cutaneous LE patients. It seems that signs of nephropathy, elevated ANA-titers and arthralgias may serve as prognostic predictors for transition into SLE.

Characteristic features of cutaneous LE are photosensitivity and female predominance. UV light is a major environmental triggering factor in cutaneous LE. Skin lesions may be induced or preexistent lesions may exacerbate due to UV light in up to 80-90% of all patients. Therefore, socioeconomic counseling of the young patients, for example choice of occupation and sun protection, are essentials in compliant patients. Also, since females are 3—6 times more frequently affected than males, the possibility of hormonal influences including pregnancy and estrogen- containing drugs should be discussed. Risk considerations for females wishing to become pregnant are required, and avoidance of estrogen-containing contraceptives should be recommended.

Key Words: Lupus erythematosus • epidemiology • cutaneous variant • risk for SLE • predictors • estrogens • socioeconomic

Lupus, Vol. 6, No. 2, 96-104 (1997)
DOI: 10.1177/096120339700600204


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
LupusHome page
Y. Bae, S-J. Yun, J-B. Lee, S-J. Kim, Y. Won, and S-C. Lee
A clinical and epidemiological study of lupus erythematosus at a tertiary referral dermatology clinic in Korea
Lupus, December 1, 2009; 18(14): 1320 - 1326.
[Abstract] [PDF]


Home page
J Am Board Fam MedHome page
S. Panjwani
Early Diagnosis and Treatment of Discoid Lupus Erythematosus
J Am Board Fam Med, March 1, 2009; 22(2): 206 - 213.
[Abstract] [Full Text] [PDF]


Home page
Arch DermatolHome page
O. Durosaro, M. D. P. Davis, K. B. Reed, and A. L. Rohlinger
Incidence of Cutaneous Lupus Erythematosus, 1965-2005: A Population-Based Study
Arch Dermatol, March 1, 2009; 145(3): 249 - 253.
[Abstract] [Full Text] [PDF]


Home page
Arch DermatolHome page
S. Moghadam-Kia, K. Chilek, E. Gaines, M. Costner, M. E. Rose, J. Okawa, and V. P. Werth
Cross-sectional Analysis of a Collaborative Web-Based Database for Lupus Erythematosus-Associated Skin Lesions: Prospective Enrollment of 114 Patients
Arch Dermatol, March 1, 2009; 145(3): 255 - 260.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Ramesh, C. G. Savva, A. Holzenburg, and J. C. Sacchettini
Crystal Structure of Rsr, an Ortholog of the Antigenic Ro Protein, Links Conformational Flexibility to RNA Binding Activity
J. Biol. Chem., May 18, 2007; 282(20): 14960 - 14967.
[Abstract] [Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
B. Qiao, J. Wu, Y. W. Chu, Y. Wang, D. P. Wang, H. S. Wu, and S. D. Xiong
Induction of systemic lupus erythematosus-like syndrome in syngeneic mice by immunization with activated lymphocyte-derived DNA
Rheumatology, September 1, 2005; 44(9): 1108 - 1114.
[Abstract] [Full Text] [PDF]


Home page
LupusHome page
J Albrecht, J A Berlin, I M Braverman, J P Callen, M I Costner, J Dutz, D Fivenson, A G Franks, J L Jorizzo, L A Lee, et al.
Dermatology position paper on the revision of the 1982 ACR criteria for systemic lupus erythematosus
Lupus, November 1, 2004; 13(11): 839 - 849.
[Abstract] [PDF]


Home page
LupusHome page
H M Al-Attia and Y H Al Ahmed
Mucocutaneous disease in Arabs with systemic lupus erythematosus: Clinical expression and relevance to autoantibodies
Lupus, October 1, 1998; 7(8): 535 - 539.
[Abstract] [PDF]



Advertisement